Landscape Capital Management L.L.C. Invests $923,000 in Masimo Co. (NASDAQ:MASI)

Landscape Capital Management L.L.C. bought a new stake in Masimo Co. (NASDAQ:MASI) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,586 shares of the medical equipment provider’s stock, valued at approximately $923,000.

A number of other institutional investors have also added to or reduced their stakes in MASI. Jones Financial Companies Lllp acquired a new position in shares of Masimo during the fourth quarter worth approximately $27,000. UMB Bank n.a. increased its stake in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont acquired a new position in Masimo during the fourth quarter worth $33,000. Blue Trust Inc. raised its holdings in Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 64 shares in the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MASI has been the topic of a number of analyst reports. Raymond James upped their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Piper Sandler increased their price objective on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Wells Fargo & Company lifted their target price on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $194.80.

Insider Activity

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. Insiders own 9.70% of the company’s stock.

Masimo Stock Performance

MASI stock opened at $144.40 on Friday. The business has a 50 day moving average of $173.64 and a 200-day moving average of $163.02. The firm has a market cap of $7.80 billion, a PE ratio of 99.59 and a beta of 1.04. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, sell-side analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.